Description

Linovio-5

• An effective once-daily treatment option in patients with T2D and severe renal impairment
• Primarily eliminated via the enterohepatic system thus no dose adjustment is needed in patients with kidney impairment as compared to sitagliptin, saxagliptin, and vildagliptin
•  Well tolerated with a low risk of hypoglycemia
•  Significant and sustained improvement in glycemic. control in patients with T2D and restore B-cell functions. Cretetes Obes letab 2001111254-207
•  Attenuates postprandial glucose levels and, with significant reductions in HbA1c after only 4 weeks of treatment.
•  Exhibits superior glucose-lowering efficacy and comparable safety and tolerability to Voglibose in patients with T2DM